Compare GSK plc (GSK) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Yum! Brands, Inc. — how do they compare? GSK plc trades at $52.71 (market cap $101.34B), while Yum! Brands, Inc. trades at $152.2 (market cap $42.05B). The key difference: GSK plc is far larger — about 2.4× Yum! Brands, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | YUM | |
|---|---|---|
Market Cap | $101.34B | $42.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $168.16 |
52-Week Low | $36.20 | $138.21 |
Enterprise Value | $121.95B | $53.32B |
Dividend Yield | 3.49% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
YUM stock trades at $158.22, down 2.15% amid news of a health investigation at Taco Bell. The company recently sold Pizza Hut for $2.7 billion to focus on KFC and Taco Bell, authorizing a $4 billion buyback. Fundamentals show steady revenue growth to $8.21B in 2025 with a 20.48% net margin, though valuation ratios appear elevated with a P/E of 24.6. Technical indicators are mixed with a bearish overall signal but RSI near oversold levels at 26.
The strategic sale of Pizza Hut could streamline operations and boost capital returns, supporting the bullish $174.60 analyst target. However, near-term sentiment is pressured by the health investigation, while high debt levels and competitive pressures in quick-service restaurants present ongoing risks. The stock's current price sits below all analyst targets, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
